Discover 658 paid clinical trials in Milwaukee, Wisconsin. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 658
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
for
Hypertension, Pregnancy-Induced
Location: Milwaukee WI, Chicago IL
Sponsor: Medical College of Wisconsin
Sex: Female
Age: 18+
Code: NCT06220721
Recruiting
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
for
Lower Respiratory Tract Infection
Location: Milwaukee WI, Kansas City KS, Philadelphia PA,
Sponsor: MeMed Diagnostics Ltd.
Sex: All
Age: 18 - 70+
Code: NCT05762302
Recruiting
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
for
Recurrent Endometrial Carcinoma,
Location: Milwaukee WI, Chicago IL, Detroit MI, Columbus OH,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT05950464
Phase 1, Recruiting
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
for
Type 2 Diabetes, Healthy Aging
Location: Milwaukee WI
Sponsor: Medical College of Wisconsin
Sex: All
Age: 18 - 70+
Code: NCT05593549
Early Phase 1, Recruiting
Peripheral Blood Flow Responses to Electromagnetic Energy
for
Exposure to Man-made Visible Light
Location: Milwaukee WI
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 18 - 59
Code: NCT02370199
Recruiting
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
for
Endometrial Cancer
Location: Milwaukee WI, Chicago IL, Warrenville IL,
Sponsor: Canadian Cancer Trials Group
Sex: Female
Age: 18+
Code: NCT05640999
Phase 2, Recruiting
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
for
Community-acquired Pneumonia
Location: Milwaukee WI, Chicago IL, Hamilton, Greater Sudbury,
Sponsor: University of Manitoba
Sex: All
Age: 18+
Code: NCT05848713
Phase 3, Recruiting
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
for
Myelodysplastic Syndrome
Location: Milwaukee WI, Grayslake IL, Lake Forest IL,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06577441
Phase 2, Recruiting
Quality of Pediatric Resuscitation in a Multicenter Collaborative
for
Cardiac Arrest, Cardiopulmonary Arrest
Location: Milwaukee WI, Chicago IL, Iowa City IA, Indianapolis IN,
Sponsor: Children's Hospital of Philadelphia
Sex: All
Age: 0 - 18
Code: NCT02708134
Recruiting
Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
for
Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8,
Location: Milwaukee WI, Chicago IL, Warrenville IL,
Sponsor: NRG Oncology
Sex: Female
Age: 18+
Code: NCT06388018
Phase 2, Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
for
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL,
Location: Milwaukee WI, Columbus OH, Canton OH, Buffalo NY,
Sponsor: Schrödinger, Inc.
Sex: All
Age: 18+
Code: NCT05544019
Phase 1, Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
for
Primary Biliary Cholangitis
Location: Milwaukee WI, Chicago IL, Iowa City IA, Rochester MN,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT06051617
Phase 3, Recruiting
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
for
Hemorrhagic Shock, Trauma Injury
Location: Milwaukee WI, St Louis MO, Columbus OH, Pittsburgh PA,
Sponsor: Philip Spinella
Sex: All
Age: 0 - 17
Code: NCT06070350
Phase 3, Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)